MRNA 'Fallen Out of Favor,' Needs New Products After Guidance Sinks

Moderna (MRNA) is on pace for its worst day ever after slashing its guidance and sharing disappointing COVID-19 vaccine forecast. Alex Coffey calls the vaccine the "only critical product" the company has had since the start of the decade, arguing it needs something more as demand plummets.

13 Jan 2025

SHARE

Schwab Network's Newsletters

Daily insights for every investor